Genomic biomarkers market to reach $50.31b by 2030

Thanks to rapid developments in next-generation sequencing and multi-omics.

The genomic biomarkers market is expected to reach $50.31b by 2030 at a compound annual growth rate of 11.6%, according to MarketsandMarkets.

The sector’s expansion is attributed to the increasing use of genomic testing in oncology, rare diseases, and inherited disorders, as well as rapid developments in next-generation sequencing (NGS) and multi-omics technologies.

Emerging advances such as AI-assisted NGS data analysis, highly automated sequencing workflows, and more sensitive liquid biopsy assays are making testing faster and more accessible for routine care, the report said.

“Regulators' focus on companion diagnostics and minimal residual disease monitoring is driving labs toward more standardised, clinically validated genomic panels that can inform treatment decisions and facilitate real-time disease tracking,” it added.

By technology, NGS held the largest market share in 2024, as hospitals, cancer centres, and pharmaceutical companies increasingly adopted it for comprehensive tumour profiling and the discovery of new prognostic and predictive biomarkers.